Current Status of Castration-Resistant Prostate Cancer Drug Therapy

IF 0.3 Q4 ONCOLOGY International Journal of Surgery-Oncology Pub Date : 2021-08-09 DOI:10.29337/ijsonco.126

Yifeng Mao, Mingqiu Hu, Gaowei Yang, Erke Gao, Wenbang Chen

{"title":"Current Status of Castration-Resistant Prostate Cancer Drug Therapy","authors":"Yifeng Mao, Mingqiu Hu, Gaowei Yang, Erke Gao, Wenbang Chen","doi":"10.29337/ijsonco.126","DOIUrl":null,"url":null,"abstract":"Objective: To explore the current therapies on castration-resistant prostate cancer (CRPC), such as drug therapy and radiotherapy. Recent Advances: Currently, CRPC is an incurable disease. CRPC treatment options available can only relieve symptoms and prolong the survival time. Because of the in-depth study of resistance mechanisms, various new drugs have been reported, including androgen synthetic inhibitor, abiraterone. Novel targeted therapy and immunotherapy have been thoroughly investigated. The recent advances in well-studied radiotherapy and chemotherapy against CRCP have also been reviewed. In this review, we have summarized new generation hormone drugs (e.g., abiraterone, enzalutamid), chemotherapeutic drugs (docetaxel), targeted therapy drugs, immunotherapy drugs (Sipulecel-T), and radioactive drugs (Radium 223). The overall treatment goals include to prolong OS, to improve quality of life, to relieve symptoms, and to prevent complications in CRCP patients. Conclusions: The use of drug therapy in combination with other drugs might improve the efficacy of CRPC treatment and might help overcome drug resistance.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2021-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgery-Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29337/ijsonco.126","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 4

Abstract

Objective: To explore the current therapies on castration-resistant prostate cancer (CRPC), such as drug therapy and radiotherapy. Recent Advances: Currently, CRPC is an incurable disease. CRPC treatment options available can only relieve symptoms and prolong the survival time. Because of the in-depth study of resistance mechanisms, various new drugs have been reported, including androgen synthetic inhibitor, abiraterone. Novel targeted therapy and immunotherapy have been thoroughly investigated. The recent advances in well-studied radiotherapy and chemotherapy against CRCP have also been reviewed. In this review, we have summarized new generation hormone drugs (e.g., abiraterone, enzalutamid), chemotherapeutic drugs (docetaxel), targeted therapy drugs, immunotherapy drugs (Sipulecel-T), and radioactive drugs (Radium 223). The overall treatment goals include to prolong OS, to improve quality of life, to relieve symptoms, and to prevent complications in CRCP patients. Conclusions: The use of drug therapy in combination with other drugs might improve the efficacy of CRPC treatment and might help overcome drug resistance.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

去势抵抗性前列腺癌药物治疗现状

目的:探讨目前治疗去势抵抗性前列腺癌(CRPC)的方法，包括药物治疗和放疗。目前，CRPC是一种无法治愈的疾病。现有的CRPC治疗方案只能缓解症状，延长生存时间。由于耐药机制的深入研究，各种新药被报道，包括雄激素合成抑制剂阿比特龙。新的靶向治疗和免疫治疗已被深入研究。本文还对近年来研究较多的CRCP放疗和化疗的进展进行了综述。本文综述了新一代激素类药物(如阿比特龙、恩杂鲁胺)、化疗药物(多西紫杉醇)、靶向治疗药物、免疫治疗药物(Sipulecel-T)和放射性药物(镭223)。CRCP患者的总体治疗目标包括延长生存期、改善生活质量、缓解症状和预防并发症。结论:药物联合其他药物治疗可提高CRPC的治疗效果，有助于克服耐药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Surgery-Oncology ONCOLOGY-

自引率

0.00%

发文量